TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01217814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT01948219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENTegral Artificial Larynx implant
Study: NCT01217814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate (MTX)
Description: Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate (MTX)
Description: Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate (MTX)
Description: Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic/folinic acid
Description: Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic/folinic acid
Description: Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic/folinic acid
Description: Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard.
Study: NCT00864383

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
Description: Moxifloxacin 400 mg Rifampicin \< 45 kg 450 mg \> 45 kg 600 mg Isoniazid 300 mg Pyrazinamide \< 40 kg 25 mg/kg rounded to nearest 500 mg\* 40-55 kg 1000 mg \> 55 kg - 75 kg 1500 mg \> 75 kg 2000 mg Ethambutol \< 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg \> 55 kg - 75 kg 1200 mg \> 75 kg 1600 mg \*For pyrazinamide dosing in patients \< 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
Description: Moxifloxacin 400 mg Rifampicin \< 45 kg 450 mg \> 45 kg 600 mg Isoniazid 300 mg Pyrazinamide \< 40 kg 25 mg/kg rounded to nearest 500 mg\* 40-55 kg 1000 mg \> 55 kg - 75 kg 1500 mg \> 75 kg 2000 mg Ethambutol \< 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg \> 55 kg - 75 kg 1200 mg \> 75 kg 1600 mg \*For pyrazinamide dosing in patients \< 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
Description: Moxifloxacin 400 mg Rifampicin \< 45 kg 450 mg \> 45 kg 600 mg Isoniazid 300 mg Pyrazinamide \< 40 kg 25 mg/kg rounded to nearest 500 mg\* 40-55 kg 1000 mg \> 55 kg - 75 kg 1500 mg \> 75 kg 2000 mg Ethambutol \< 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg \> 55 kg - 75 kg 1200 mg \> 75 kg 1600 mg \*For pyrazinamide dosing in patients \< 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm.
Study: NCT00913497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glulisine
Description: Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
Study: NCT00879034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib
Description: Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
Study: NCT02672878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold
Study: NCT02331589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRG (Korea Red ginseng)
Description: 3 weeks of KRG capsule (3,000 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for KRG)
Description: Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
Study: NCT00293813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70 mg PO QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: denosumab 60 mg SC q 6 mos

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for alendronate and placebo for denosumab
Study: NCT01581229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: noninvasive positive pressure ventilation
Description: Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen therapy
Description: In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
Study: NCT02715830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty of distal arteries
Description: angioplasty of the arteries bellow-the-knee

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty of distal arteries
Description: angioplasty of the arteries bellow-the-knee
Study: NCT03866317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: All subjects will receive secukinumab 300 mg injections subcutaneously at week 0, 1, 2, 3, 4, then every 4 weeks until week 12.
Study: NCT04120844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)-based patient empowerment program (PEP)
Description: Motivational interviewing (MI) is a collaborative, patient-centered counseling approach that aims to elicit behavior change. Counselors use empathy and other techniques to create an atmosphere to help patients to explore the discrepancies between the goals and their current behavior. The focus of MI is to find and resolve the ambivalence, improve patients' perception of the importance of behavior change, and support them to make the change. MI provides a structural framework with guiding principles that can be easily followed by the primary care doctors. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Traditional lecture style health education
Description: The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI. We consciously avoided the inclusion of elements of self-reflection and motivation in these lectures.
Study: NCT02841007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko neuromuscular electrostimulation device
Study: NCT04317443

Intervention type: PROCEDURE
Intervention: Super-mini percutaneous nephrolithotomy (SMP)
Description: SMP will be performed under general anesthesia in prone/supine position. Renal puncture will be performed under ultrasound/fluoroscopy guidance based on the preference of the participating surgeon. Tracts will be dilated to 14 Fr. Stone fragmentation will be performed with holmium laser and fragments will be extracted with the active suction system. For the exit strategy, placement of a nephrostomy tube or JJ stent will be decided by the participating surgeon.

Intervention type: PROCEDURE
Intervention: Extracorporeal Shock Wave Lithotripsy (ESWL)
Description: ESWL will be performed under sedation/analgesia, shock wave lithotripsy parameters will be determined based on the device and the settings of local center. For patients requiring multiple sessions, maximum 3 (or more) sessions will be allowed. Ureteral stenting prior to ESWL will be performed based on the decision of the participating center.
Study: NCT02295631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard tracheal tube
Description: ETI with standard tracheal tube and Macintosh laryngoscope
Study: NCT02066246

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirSeal
Description: 100 patients are treated with the AirSeal insufflation and trocar system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Olympus UHI-3
Description: 100 patients are treated with a conventional insufflation and trocar system
Study: NCT01022632

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
Study: NCT01022632

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin and Fluoxetine
Description: Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
Study: NCT04391127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine: 400 mg PO every 12 hours for one day. Subsequently 200 mg every 12 hours per 4 more days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 12 mg PO every 24 hours for one day (in case of weight less than 80 kg) or 18 mg PO every 24 hours for one day (in case of weight over 80 kg) Subsequently this group will take two tablets of placebo 12 hrs after ivermectin ingestion and then one tablet of placebo each 12 hrs per 4 more days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 12 mg PO every 24 hours for one day (in case of weight less than 80 kg) or 18 mg PO every 24 hours for one day (in case of weight over 80 kg) Subsequently this group will take two tablets of placebo 12 hrs after ivermectin ingestion and then one tablet of placebo each 12 hrs per 4 more days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two tablets of placebo PO every 12 hours for one day. Subsequently one tablet of placebo every 12 hours per 4 more days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two tablets of placebo PO every 12 hours for one day. Subsequently one tablet of placebo every 12 hours per 4 more days.
Study: NCT03802669

Intervention type: OTHER
Intervention: oral mutans streptococcus
Description: quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern

Intervention type: OTHER
Intervention: oral mutans streptococcus
Description: quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern

Intervention type: OTHER
Intervention: oral mutans streptococcus
Description: quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern

Intervention type: OTHER
Intervention: oral mutans streptococcus
Description: quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern

Intervention type: OTHER
Intervention: oral mutans streptococcus
Description: quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern

Intervention type: OTHER
Intervention: oral mutans streptococcus
Description: quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern
Study: NCT01889004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Escalating concentrations until loss of responsiveness

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Escalating concentrations until loss of responsiveness
Study: NCT03170401

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: enteral protein supplementation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard enteral nutrition
Description: Standard enteral nutrition.
Study: NCT02034292

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APD791

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04480918

Intervention type: DEVICE
Intervention: Electroconvulsive Therapy (ECT)
Description: ECT for the treatment of treatment-resistant depression OR Bipolar Disorder in an active major depressive episode

Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS for the treatment of treatment-resistant depression in an active major depressive episode

Intervention type: DRUG
Intervention: Ketamine
Description: Intravenous ketamine infusion for the treatment of treatment-resistant depression in an active major depressive episode

Intervention type: DRUG
Intervention: Esketamine
Description: Intranasal esketamine insufflation for the treatment of treatment-resistant depression in an active major depressive episode

Intervention type: DEVICE
Intervention: Deep Transcranial Magnetic Stimulation (dTMS)
Description: TMS for the treatment of OCD
Study: NCT00499577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV pp65 peptide
Description: Given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV pp65 peptide
Description: Given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV pp65 peptide
Description: Given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV pp65 peptide
Description: Given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hTERT I540/R572Y/D988Y multipeptide vaccine
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hTERT I540/R572Y/D988Y multipeptide vaccine
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal polyvalent vaccine
Description: Given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal polyvalent vaccine
Description: Given intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: survivin Sur1M2 peptide vaccine
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: survivin Sur1M2 peptide vaccine
Description: Given subcutaneously
Study: NCT00894660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine (Test)
Description: Oral tablet, single dose, 1 X 300 MG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine (Comparator)
Description: Oral tablet, single dose, 2 X 150 MG
Study: NCT00820690

Intervention type: DRUG
Intervention: doxorubicin
Description: 4 cycles AC: doxorubicin 60mg/m2
Study: NCT00580593

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP® S/T System
Description: The BiPAP® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham-NIPPV
Description: a sham-device
Study: NCT04969458

Intervention type: OTHER
Intervention: survey application
Description: Data collection tools used in the study;~* Clinic and Demographic Evaluation Form~* Oswestry Low Back Pain Disability Index (ODI)~* Patterns of Activity Measure Pain (POAM-P)~* Roland-Morris Disability Questionnaire (RMDQ)~* Hospital Anxiety and Depression Scale (HADS)~* Graded Chronic Pain Scale Version 2.0 (GCPS 2.0)
Study: NCT00712270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Target dose = 15mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Target Dose = 2mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
Study: NCT02020304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined spinal epidural
Description: Combined Spinal Epidural

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined spinal epidural
Description: Combined Spinal Epidural
Study: NCT02467660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Using study-provided iPod device to listen to guided meditations daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health & Wellness Education
Description: Using study-provided iPod device to listen to educational podcasts daily
Study: NCT02295631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView VivaSight SL
Description: ETI with ETView VivaSight SL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView VivaSight SL
Description: ETI with ETView VivaSight SL
Study: NCT00106119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liothyronine and Levothyroxine
Description: Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases
Study: NCT02364245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinect
Description: Receive computer games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
Study: NCT05187572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group intervention
Description: This intervention was developed during 14 sessions, held twice a week, with a duration of 45 to 60 minutes each. The sessions were developed as group-based interventions, facilitated by a leader and a co-leader from each community institution.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group intervention
Description: This intervention was developed during 14 sessions, held twice a week, with a duration of 45 to 60 minutes each. The sessions were developed as group-based interventions, facilitated by a leader and a co-leader from each community institution.
Study: NCT00836524

Intervention type: PROCEDURE
Intervention: ultrasound
Description: 4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
Study: NCT01775800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment modification
Study: NCT02485067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THVD-201
Description: Combination of Tolterodine 2mg and Pilocarpine 9mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THVD-201
Description: Combination of Tolterodine 2mg and Pilocarpine 9mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(For THVD-201)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detrusitol 2mg tablet
Description: Tolterodine 2mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(For Detrusitol 2mg tablet)
Study: NCT01165294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.